General Information of Drug (ID: DMG7YQL)

Drug Name
GSK2245840 Drug Info
Synonyms
Gepirone hydrochloride; GEPIRONE HYDROCHLORIDE; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,
Indication
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Phase 2 [1]
Cross-matching ID
PubChem CID
25108829
CAS Number
CAS 1093403-33-8
TTD Drug ID
DMG7YQL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Resveratrol DM3RWXL Giant cell arteritis 4A44.2 Phase 3 [3]
SEN-196 DMLDBQ5 Huntington disease 8A01.10 Phase 2 [4]
MB-12066 DMRSN2C Obesity 5B81 Phase 2 [5]
SRT2379 DM7DAKX Type-2 diabetes 5A11 Phase 1 [6]
SRT3025 DMRAXFH Type-2 diabetes 5A11 Phase 1 [7]
PMID25435179-Compound-WO2012106509Salermide DMLAH39 N. A. N. A. Patented [3]
CAMBINOL DMW46GY Discovery agent N.A. Patented [8]
PMID25435179-Compound-WO2012106509CAY10602 DM2F1T0 N. A. N. A. Patented [3]
PMID25435179-Compound-WO2012106509Tenovin-6 DMBSOED N. A. N. A. Patented [3]
GSK184072 DMMIR1K Colon cancer 2B90.Z Discontinued in Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
NAD-dependent deacetylase sirtuin-1 (SIRT1) TTUF2HO SIR1_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT01154101) Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis. U.S. National Institutes of Health.
2 Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52.
3 Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
4 Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen. 2011 Dec;16(10):1153-69.
5 Pharmacological activation of Sirt1 ameliorates polyglutamine-induced toxicity through the regulation of autophagy.PLoS One.2013 Jun 10;8(6):e64953.
6 SRT2379, a small-molecule SIRT1 activator, fails to reduce cytokine release in a human endotoxemia model. Critical Care 2013, 17(Suppl 4):P8.
7 The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391.
8 Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem. 2009 May 14;52(9):2673-82.
9 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).